🔗 Share this article

The recently developed medications for gonorrhoea in decades are being viewed as a "major milestone" in the effort against drug-resistant strains of the infection, according to researchers.

A Global Challenge

Cases of gonorrhoea are escalating worldwide, with estimates suggesting more than 82 million new cases per year. Particularly high rates are seen in the African continent and countries within the WHO's Western Pacific region, which spans from China and Mongolia to New Zealand. Across England, cases have reached a record high, while rates across Europe in 2023 were three times higher compared to figures for 2014.

“The authorization of fresh medications for gonorrhoea is an critical and opportune development in the reality of increasing worldwide cases, increasing antimicrobial resistance and the very limited available drugs presently on offer.”

Medical experts are deeply concerned about the rise in antibiotic-resistant strains. The WHO has classified it as a "priority pathogen". Ongoing monitoring found that the effectiveness of key first-line drugs like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

A Pair of Novel Drugs Gain Approval

One new antibiotic, alternatively called Nuzolvence, was approved by the US Food and Drug Administration in December for combating gonorrhoea. This disease can lead to significant complications, including infertility. Scientists hope that targeted use of this new drug will help slow the spread of drug resistance.

Gepotidacin, originating from the pharmaceutical company GlaxoSmithKline, was also approved in the same week. This drug, which is additionally indicated for UTIs, was shown in trials to be effective against superbug versions of the gonorrhoea bacteria.

An Innovative Partnership

This new treatment stemmed from a innovative non-profit model for drug creation. The non-profit organisation Global Antibiotic Research & Development Partnership partnered with the pharmaceutical company Innoviva to see it through.

“This authorization represents a significant shift in the management of multidrug-resistant gonorrhoea, which until now has been staying ahead of antibiotic development.”

Research Study Outcomes and Global Access

According to results detailed in a major medical journal, the new drug eradicated over nine in ten of genital gonorrhoea infections. This places it at an similar efficacy with the existing first-line therapy, which involves an injection and a pill. The research included nearly 1,000 volunteers from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its collaboration, GARDP has the rights to license and sell the drug in many low-income and middle-income countries.

Clinicians treating patients have shared hope. The availability of a single-dose, oral treatment of this kind is hailed as a "critical tool" for gonorrhoea control. This is deemed essential to alleviate the strain of the illness for people and to stop the proliferation of highly drug-resistant gonorrhoea worldwide.